File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting

TitleReal-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
Authors
Keywordsasthma
bronchiectasis
COPD
COVID-19
molnupiravir
nirmatrelvir–ritonavir
Issue Date23-Feb-2023
PublisherMDPI
Citation
Viruses, 2023, v. 15, n. 3 How to Cite?
Abstract

While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. A territory-wide retrospective cohort study was conducted in Hong Kong to investigate the efficacy of MOV and NMV-r against severe outcomes of COVID-19 in unvaccinated adult patients with chronic respiratory diseases. A total of 3267 patients were included. NMV-r was effective in preventing respiratory failure (66.6%; 95% CI, 25.6–85.0%, p = 0.007), severe respiratory failure (77.0%; 95% CI, 6.9–94.3%, p = 0.039) with statistical significance, and COVID-19 related hospitalization (43.9%; 95% CI, −1.7–69.0%, p = 0.057) and in-hospital mortality (62.7%; 95% CI, −0.6–86.2, p = 0.051) with borderline statistical significance. MOV was effective in preventing COVID-19 related severe respiratory failure (48.2%; 95% CI 0.5–73.0, p = 0.048) and in-hospital mortality (58.3%; 95% CI 22.9–77.4, p = 0.005) but not hospitalization (p = 0.16) and respiratory failure (p = 0.10). In summary, both NMV-r and MOV are effective for reducing severe outcomes in unvaccinated COVID-19 patients with chronic respiratory diseases.


Persistent Identifierhttp://hdl.handle.net/10722/329013
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.140
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwok, Wang Chun-
dc.contributor.authorTsoi, Man Fung-
dc.contributor.authorLeung, Sze Him Isaac-
dc.contributor.authorTsui, Chung Ki-
dc.contributor.authorTam, Terence Chi Chun-
dc.contributor.authorHo, James Chung Man-
dc.contributor.authorLam, David Chi Leung-
dc.contributor.authorIp, Mary Sau Man-
dc.contributor.authorHo, Pak Leung-
dc.date.accessioned2023-08-05T07:54:37Z-
dc.date.available2023-08-05T07:54:37Z-
dc.date.issued2023-02-23-
dc.identifier.citationViruses, 2023, v. 15, n. 3-
dc.identifier.issn1999-4915-
dc.identifier.urihttp://hdl.handle.net/10722/329013-
dc.description.abstract<p>While molnupiravir (MOV) and nirmatrelvir–ritonavir (NMV-r) were developed for treatment of mild to moderate COVID-19 infection, there has been a lack of data on the efficacy among unvaccinated adult patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. A territory-wide retrospective cohort study was conducted in Hong Kong to investigate the efficacy of MOV and NMV-r against severe outcomes of COVID-19 in unvaccinated adult patients with chronic respiratory diseases. A total of 3267 patients were included. NMV-r was effective in preventing respiratory failure (66.6%; 95% CI, 25.6–85.0%, p = 0.007), severe respiratory failure (77.0%; 95% CI, 6.9–94.3%, p = 0.039) with statistical significance, and COVID-19 related hospitalization (43.9%; 95% CI, −1.7–69.0%, p = 0.057) and in-hospital mortality (62.7%; 95% CI, −0.6–86.2, p = 0.051) with borderline statistical significance. MOV was effective in preventing COVID-19 related severe respiratory failure (48.2%; 95% CI 0.5–73.0, p = 0.048) and in-hospital mortality (58.3%; 95% CI 22.9–77.4, p = 0.005) but not hospitalization (p = 0.16) and respiratory failure (p = 0.10). In summary, both NMV-r and MOV are effective for reducing severe outcomes in unvaccinated COVID-19 patients with chronic respiratory diseases.</p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofViruses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectasthma-
dc.subjectbronchiectasis-
dc.subjectCOPD-
dc.subjectCOVID-19-
dc.subjectmolnupiravir-
dc.subjectnirmatrelvir–ritonavir-
dc.titleReal-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting-
dc.typeArticle-
dc.identifier.doi10.3390/v15030610-
dc.identifier.scopuseid_2-s2.0-85151180552-
dc.identifier.volume15-
dc.identifier.issue3-
dc.identifier.eissn1999-4915-
dc.identifier.isiWOS:000958252800001-
dc.identifier.issnl1999-4915-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats